

BOARD OF PHARMACY

Open Session Agenda

OCTOBER 2, 2025

9:30AM

VIRTUAL MEETING NOTICE

Information on how to access the public portion of the meeting virtually is listed below:

Join by Web:

<https://dcnet.webex.com/dcnet/j.php?MTID=m74cb67faf1832dc307116f4c5e139e06>

Join by Phone:

+1-202-860-2110 United States Toll (Washington D.C.)

1-650-479-3208 Call-in number (US/Canada)

Access Code:

230 167 43168

BOARD MISSION STATEMENT:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing, through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.

The Open Session Agenda continues on the next page with the ‘Board Meeting Participants’.

BOARD MEETING PARTICIPANTS:

BOARD MEMBERS:	
Dr. Allison Hill, Pharm. D. R.PH, Chairperson	
Dr. Benjamin Miles, Pharm. D. R.PH	
Dr. Jamila Jorden, Pharm. D. R. PH	
Mr. Rodrick McGill, Esq., Consumer Member	
VACANT (Pharmacist Member)	
VACANT (Pharmacist Member)	
VACANT (Pharmacy Tech Member)	
BOARD STAFF:	
Aisha Nixon– Associate Director	
Ericka Walker- Executive Director	
Karin Barron – Health Licensing Specialist	
Luanne Greenaway – Health Licensing Specialist	
Dr. Monai Lowe, Pharm. D. R.PH – PDMP Pharmacist	
Lisa Robinson – Compliance Coordinator	
Countee Gilliam – Investigator	
LEGAL STAFF:	
Carla Williams, Esq. – Senior Assistant General Counsel	
DC HEALTH STAFF:	
Warner Dixon, Office of Government Affairs	

The Open Session Agenda continues on the next page with the 'Call to Order'.

CALL TO ORDER

OS-25-10-01	<u>INTRODUCTIONS</u>	
ALL	A. BOARD MEMBERS B. BOARD STAFF	

APPROVAL OF MINUTES, CONSENT AGENDA, BOARD POLICIES, AND STAFF REPORTS

OS-25-10-02	<u>BOARD/DEPARTMENT REPORT</u>	EW
ALL	A. BOARD CHAIR'S REPORT B. EXECUTIVE DIRECTOR'S REPORT i. DC Health Updates The Executive Director will provide an update on the District of Columbia responses to public health issues/concerns. ii. PDMP UPDATE The PDMP Pharmacist will provide an update on the PDMP. iii. Board Vacancies/MOTA Update The Executive Director will provide an update on current Board vacancies. iv. Licensure Census The Executive Director provided an update on the current licensure census in the District of Columbia. C. BOARD ATTORNEY'S REPORT D. OFFICE OF GOVERNMENT RELATION'S REPORT Council Updates • On September 15, the Council resumed their regular legislative business after being on recess. • On September 17, the Council held a Legislative meeting and Committee of the Whole hearing.	

	○ Councilmember Henderson’s <i>Community Health Temporary Amendment Act of 2025</i> (B26-) was on the agenda. Community Health Temporary Amendment Act of 2025 • Councilmember Henderson introduced the <i>Community Health Temporary Amendment Act of 2025</i> (B26-) on September 15, 2025. ○ The legislation amends the District of Columbia Health Occupations Revisions Act of 1985 and the Consent for Vaccinations of Minors Amendment Act of 2022 to authorize healthcare providers in the District to order and administer immunizations recommended by competent medical and public health organizations designated by the Director of the Department of Health. The legislation will also allow pharmacies to administer the COVID-19 vaccine without a doctor’s prescription. • The legislation has been referred to the Committee on Health. A hearing has not been scheduled yet. Upcoming Advisory Committee on Immunization Practices (ACIP) Meeting • The CDC’s ACIP will meet on September 18 and 19 to discuss schedules and recommendations for Measles, Mumps, Rubella, and Varicella (MMRV), Hepatitis B, and COVID-19 vaccines. ACIP will also vote on the recommendations. • OGR will provide a high-level summary of the meeting and ACIP’s recommendations. Federal Updates: • On September 9, HHS Secretary Robert F. Kennedy, Jr. and the Make America Healthy Again Commission released the Make America Healthy Again Strategy Report. ○ The Strategy Report contains 120 recommendations grouped into four categories: Advance Research, Realign Incentives, Foster Private Sector Collaboration, and Increase Public Awareness. ○ Most of the recommendations call for collaboration between the NIH, FDA, EPA, USDA, CDC, the VA, and HHS.	
OS-25-10-03	<u>OPEN SESSION AGENDA</u>	KB/AN
ALL	Board Action: Consideration of the October 2, 2025 Open Session agenda.	

OS-25-10-04 ALL	<u>OPEN SESSION MINUTES</u> Board Action: Consideration of the Open Session minutes from the following, meetings: • August 7, 2025, Open Session Meeting Minutes • September 4, 2025, Open Session Meeting Minutes Background: The Open Session Minutes are a record of the Board’s past meeting(s), describing the events, list of attendees; a statement of the issues considered and related responses or decisions of the Board.	KB/AN
OS-25-10-05 ALL	<u>OPEN CONSENT AGENDA</u> Board Action: Consideration of the current open Consent Agenda items for purposes of review and/or ratification of Board actions taken since the last Board meeting. Background: The Open Consent Agenda is a record of the decisions and/or actions taken by the Board or its staff since the last meeting of the Board.	EW/AN
OS-25-10-06 ALL	<u>FY26 BOARD OF PHARMACY MEETING DATES</u> Board Action: Consideration of the proposed meeting schedule for Fiscal Year 2026 (FY26). Background: The Board of Pharmacy customarily meets on the first Thursday of each month, with the following exceptions: • No meeting is held in July or August to accommodate summer scheduling conflicts. Board will decide which month will have a break. • The January and July meeting dates should be discussed due to falling on a holiday or close to a holiday. The Board of Pharmacy will hold one in-person (IP) meeting per quarter during Fiscal Year 2026. All other meetings will be conducted virtually. Members of the public will continue to have the ability to attend all meetings virtually, including those held in person.	EW

	<table><tr><th>Month</th><th>Meeting Date</th><th>V or IP</th></tr><tr><td>October 2026</td><td>10/02/2025</td><td>V</td></tr><tr><td>November 2026</td><td>11/06/2025</td><td>V</td></tr><tr><td>December 2026</td><td>12/04/2025</td><td>IP</td></tr><tr><td>January 2026</td><td>TBD</td><td>V</td></tr><tr><td>February 2026</td><td>02/05/2026</td><td>V</td></tr><tr><td>March 2026</td><td>03/05/2026</td><td>V</td></tr><tr><td>April 2026</td><td>04/02/2026</td><td>IP</td></tr><tr><td>May 2026</td><td>05/07/2026</td><td>V</td></tr><tr><td>June 2026</td><td>06/04/2026</td><td>V</td></tr><tr><td>July 2026</td><td>07/02/2026</td><td></td></tr><tr><td>August 2026</td><td>08/07/2026</td><td>IP</td></tr><tr><td>September 2026</td><td>09/03/2026</td><td>V</td></tr></table>	Month	Meeting Date	V or IP	October 2026	10/02/2025	V	November 2026	11/06/2025	V	December 2026	12/04/2025	IP	January 2026	TBD	V	February 2026	02/05/2026	V	March 2026	03/05/2026	V	April 2026	04/02/2026	IP	May 2026	05/07/2026	V	June 2026	06/04/2026	V	July 2026	07/02/2026		August 2026	08/07/2026	IP	September 2026	09/03/2026	V	
Month	Meeting Date	V or IP																																							
October 2026	10/02/2025	V																																							
November 2026	11/06/2025	V																																							
December 2026	12/04/2025	IP																																							
January 2026	TBD	V																																							
February 2026	02/05/2026	V																																							
March 2026	03/05/2026	V																																							
April 2026	04/02/2026	IP																																							
May 2026	05/07/2026	V																																							
June 2026	06/04/2026	V																																							
July 2026	07/02/2026																																								
August 2026	08/07/2026	IP																																							
September 2026	09/03/2026	V																																							
OS-25-10-08	<u>NABP E-NEWSLETTERS</u>	AH																																							
ALL	Board Action: No action required Background: Highlights for the September NABP E-Newsletters. September 10, 2025 FDA’s New ‘Green List’ Aims to Prevent Unverified GLP-1 APIs From Entering US Many Pharmacies Lack Key Opioid Treatment Medication FIP Statement of Policy Recognizes the Role of Pharmacists in the Fight Against NCDs New FIP Policy Stresses Privacy and Security in AI Use Flu Vaccine Not Associated with Heart Inflammation, Studies Show Single Dose of PCV Proves Effective Against IPD in Children Advance Your Knowledge with NABP Home Study Webinars																																								

	September 17, 2025 FDA Releases Draft Guidance on Increasing Non-Opioid Alternative Treatments for Chronic Pain Dr. Lorna Breen Heroes’ Foundation Publishes Report Revealing Barriers Stopping Some Health Care Providers from Seeking Mental Health Care HHS Develops Pilot Initiative to Tackle Hepatitis C in Individuals With SUD ‘Operation Genuine Valor’ Aims to Protect Veterans from Counterfeit Medications Innovations: Solving the Puzzle of Chronic Medication Shortages’ Prioritize ‘Patient Safety from the Start’ This World Patient Safety Day Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.	
OS-25-10-09 ALL	<u>PUBLIC COMMENTS</u> Background: To provide the public with the opportunity to comment on or provide feedback to the Board.	

MOTION TO CLOSE

OS-25-10-09 ALL	<u>MOTION TO CLOSE</u> Board Action: “Maidam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).” ROLL CALL VOTE	
------------------------	---	--

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at : am

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.

The Open Session Agenda continues on the next page with 'Motion to Adjourn'. The next Board meeting is **VIRTUAL and will be held on **November 6, 2025**.**

MOTION TO ADJOURN

OS-25-09-10	<u>MOTION TO ADJOURN</u>	
ALL	Board Action: To adjourn the meeting. Background: At the end of every meeting, a motion to adjourn must be made in open session to close out the business of the Board.	

This ends the Open Session Agenda.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov. 3 DCMR § 10409.2